Checkpoint Capital’s Immunocore IMCR Stock Holding History

Checkpoint Capital’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,011	Closed	-$267K	–	10
2025 Q1	$267K	Buy	+9,011	New	+$270K	0.15%	13

Other funds holding IMCR

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Checkpoint Capital's IMCR Position: Q2 2025 in Review

Checkpoint Capital sold out of Immunocore (IMCR) in Q2 2025, closing a stake of 9,011 shares — an estimated $267K sold.

Checkpoint Capital first reported a position in IMCR in Q1 2025 and held it in 1 quarter. The position peaked at $267K in Q1 2025. 133 funds tracked by Wall St. Rank hold IMCR as of Q2 2025.

Checkpoint Capital reported no remaining Immunocore position as of Q2 2025 after selling out during the quarter.
Checkpoint Capital sold 9,011 Immunocore shares in Q2 2025, an estimated $267K.
Checkpoint Capital first reported a position in Immunocore in Q1 2025 and held it in 1 quarter.
Checkpoint Capital's Immunocore position peaked at $267K in Q1 2025.
133 funds tracked by Wall St. Rank held Immunocore as of Q2 2025.

Based on Checkpoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.